2026-10-29T12:15:54.000Z · 5 days ago BioAffinity highlights importance of early lung cancer detection, treatment
Oct 29, 2026, 8:00 AM EDT · 5 days ago bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
2026-10-15T12:16:30.000Z · 19 days ago BioAffinity to present new perspectives on CyPath Lung at CHEST 2026
Oct 15, 2026, 8:00 AM EDT · 19 days ago bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026
Oct 13, 2026, 8:00 AM EDT · 21 days ago bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Oct 9, 2026, 12:30 PM EDT · 24 days ago WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-09T15:40:22.000Z · 24 days ago BioAffinity Technologies announces closing of $4M registered direct financing
Oct 9, 2026, 11:37 AM EDT · 24 days ago bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Oct 8, 2026, 1:30 PM EDT · 25 days ago WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08T16:10:33.000Z · 25 days ago bioAffinity Technologies Inc trading halted, volatility trading pause
2026-10-08T16:10:16.000Z · 25 days ago BioAffinity Technologies announces $4M registered direct offering
Oct 8, 2026, 12:07 PM EDT · 25 days ago bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08T12:15:23.000Z · 26 days ago BioAffinity announces Japan Patent Office issued notice of allowance for CyPath
Oct 8, 2026, 8:00 AM EDT · 26 days ago bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
2026-10-06T13:25:42.000Z · 4 weeks ago BioAffinity reports over 100% growth in CyPath Lung sales through Q3
Oct 6, 2026, 9:19 AM EDT · 4 weeks ago bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
2026-09-30T12:15:31.000Z · 4 weeks ago BioAffinity, AvMEDICAL deliver joint exhibition of CyPath Lung
Sep 30, 2026, 8:00 AM EDT · 4 weeks ago bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
2026-09-22T12:25:53.000Z · 6 weeks ago BioAffinity to present clinical, veteran-focused data on CyPath Lung
Sep 22, 2026, 8:00 AM EDT · 6 weeks ago bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
2026-09-17T16:30:35.000Z · 6 weeks ago bioAffinity Technologies Inc trading halted, volatility trading pause
2026-09-17T12:10:33.000Z · 6 weeks ago BioAffinity Technologies announces grant of Hong Kong patent for CyPath Lung
Sep 17, 2026, 8:00 AM EDT · 6 weeks ago bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
2026-09-09T12:15:15.000Z · 7 weeks ago BioAffinity Technologies regains compliance with Nasdaq listing requirements
Sep 9, 2026, 8:00 AM EDT · 7 weeks ago bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
2026-09-04T15:10:20.000Z · 2 months ago bioAffinity Technologies Inc trading halted, volatility trading pause
Sep 3, 2026, 4:30 PM EDT · 2 months ago bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 1, 2026, 8:00 AM EDT · 2 months ago bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
Aug 20, 2026, 8:00 AM EDT · 2 months ago bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
Aug 18, 2026, 8:00 AM EDT · 2 months ago bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
Aug 14, 2026, 11:45 AM EDT · 2 months ago WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Aug 14, 2026, 11:07 AM EDT · 2 months ago bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Aug 13, 2026, 10:00 AM EDT · 2 months ago WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Aug 13, 2026, 9:07 AM EDT · 2 months ago bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Aug 7, 2026, 8:00 AM EDT · 2 months ago bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Jul 27, 2026, 8:08 AM EDT · 3 months ago bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
Jul 22, 2026, 8:08 AM EDT · 3 months ago bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD
Jul 7, 2026, 8:46 AM EDT · 3 months ago bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
Jun 22, 2026, 8:00 AM EDT · 4 months ago bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
Jun 18, 2026, 2:54 PM EDT · 4 months ago WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
Jun 18, 2026, 1:16 PM EDT · 4 months ago bioAffinity Technologies Announces Closing of $3.2 Million Offering
Jun 17, 2026, 10:41 AM EDT · 4 months ago WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
Jun 17, 2026, 9:25 AM EDT · 4 months ago bioAffinity Technologies Announces Pricing of $3.2 Million Offering
Jun 16, 2026, 8:06 AM EDT · 4 months ago bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
Jun 2, 2026, 8:00 AM EDT · 5 months ago Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
May 27, 2026, 8:00 AM EDT · 5 months ago bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
May 12, 2026, 9:15 AM EDT · 5 months ago bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
May 8, 2026, 8:30 AM EDT · 5 months ago bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
Apr 28, 2026, 9:16 AM EDT · 6 months ago bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
Apr 14, 2026, 8:00 AM EDT · 6 months ago New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
Apr 7, 2026, 8:00 AM EDT · 7 months ago bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
Apr 1, 2026, 8:00 AM EDT · 7 months ago bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
Mar 25, 2026, 8:00 AM EDT · 7 months ago bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
Mar 17, 2026, 7:45 AM EDT · 7 months ago New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
Mar 13, 2026, 8:00 AM EDT · 7 months ago bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
Mar 10, 2026, 7:47 AM EDT · 7 months ago bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
Mar 3, 2026, 8:30 AM EST · 8 months ago bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
Feb 25, 2026, 8:30 AM EST · 8 months ago bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
Feb 19, 2026, 11:00 AM EST · 8 months ago New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
Feb 17, 2026, 8:00 AM EST · 8 months ago Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study
Feb 9, 2026, 8:00 AM EST · 8 months ago bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
Jan 7, 2026, 8:00 AM EST · 10 months ago bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
Dec 3, 2025, 8:00 AM EST · 11 months ago bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable